Juana Hernandez

Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

J. Soria, G. Mountzios, P. Fouret, 2007, Clinical Cancer Research.

ExcisionRepairCrossComplementationGroup 1 Immunohistochemical ExpressionPredictsObjectiveResponseandCancer-SpecificSurvival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally AdvancedHeadandNeck SquamousCell Carcinoma

J. Soria, P. Fouret, A. Handra‐Luca, 2007 .

Desensitization and Induction Immunosuppressive Therapy in Highly HLA-Sensitized Patients Receiving Cadaveric Renal Allograft)

D. Marrero, J. M. Delgado, Juana Hernandez, 2011 .

DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer

M. Mathieu, F. André, P. Nuciforo, 2010, American journal of clinical oncology.

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.

A retrospective study on the management of patients with rituximab refractory follicular lymphoma

X. Troussard, P. Solal-Céligny, A. Bardet, 2018, British journal of haematology.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Thomas Bachelot, Thierry Petit, Pierre Kerbrat, 2014, The Lancet. Oncology.

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.